241 related articles for article (PubMed ID: 21870818)
1. Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer.
Battistutta R; Cozza G; Pierre F; Papinutto E; Lolli G; Sarno S; O'Brien SE; Siddiqui-Jain A; Haddach M; Anderes K; Ryckman DM; Meggio F; Pinna LA
Biochemistry; 2011 Oct; 50(39):8478-88. PubMed ID: 21870818
[TBL] [Abstract][Full Text] [Related]
2. Oligo-aspartic acid conjugates with benzo[c][2,6]naphthyridine-8-carboxylic acid scaffold as picomolar inhibitors of CK2.
Vahter J; Viht K; Uri A; Enkvist E
Bioorg Med Chem; 2017 Apr; 25(7):2277-2284. PubMed ID: 28274673
[TBL] [Abstract][Full Text] [Related]
3. Discovery and SAR of 5-(3-chlorophenylamino)benzo[c][2,6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Anderes K; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Trent K; Rice WG; Ryckman DM
J Med Chem; 2011 Jan; 54(2):635-54. PubMed ID: 21174434
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 5-(3-Chlorophenylamino)benzo[
Wang Y; Lv Z; Chen F; Wang X; Gou S
J Med Chem; 2021 Apr; 64(8):5082-5098. PubMed ID: 33834781
[TBL] [Abstract][Full Text] [Related]
5. Pre-clinical characterization of CX-4945, a potent and selective small molecule inhibitor of CK2 for the treatment of cancer.
Pierre F; Chua PC; O'Brien SE; Siddiqui-Jain A; Bourbon P; Haddach M; Michaux J; Nagasawa J; Schwaebe MK; Stefan E; Vialettes A; Whitten JP; Chen TK; Darjania L; Stansfield R; Bliesath J; Drygin D; Ho C; Omori M; Proffitt C; Streiner N; Rice WG; Ryckman DM; Anderes K
Mol Cell Biochem; 2011 Oct; 356(1-2):37-43. PubMed ID: 21755459
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of CX-4945 binding to human protein kinase CK2.
Ferguson AD; Sheth PR; Basso AD; Paliwal S; Gray K; Fischmann TO; Le HV
FEBS Lett; 2011 Jan; 585(1):104-10. PubMed ID: 21093442
[TBL] [Abstract][Full Text] [Related]
7. Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cells.
Zanin S; Borgo C; Girardi C; O'Brien SE; Miyata Y; Pinna LA; Donella-Deana A; Ruzzene M
PLoS One; 2012; 7(11):e49193. PubMed ID: 23145120
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Pivotal Role of the CK2 Hinge Region Sub-Pocket in Binding with Tricyclic Quinolone Analogues by Computational Analysis.
Zhou Y; Zhang N; Tang S; Qi X; Zhao L; Zhong R; Peng Y
Molecules; 2017 May; 22(5):. PubMed ID: 28534839
[TBL] [Abstract][Full Text] [Related]
9. CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy.
Siddiqui-Jain A; Drygin D; Streiner N; Chua P; Pierre F; O'Brien SE; Bliesath J; Omori M; Huser N; Ho C; Proffitt C; Schwaebe MK; Ryckman DM; Rice WG; Anderes K
Cancer Res; 2010 Dec; 70(24):10288-98. PubMed ID: 21159648
[TBL] [Abstract][Full Text] [Related]
10. Protein kinase CK2 in health and disease: Structural bases of protein kinase CK2 inhibition.
Battistutta R
Cell Mol Life Sci; 2009 Jun; 66(11-12):1868-89. PubMed ID: 19387547
[TBL] [Abstract][Full Text] [Related]
11. Discovery and design of tricyclic scaffolds as protein kinase CK2 (CK2) inhibitors through a combination of shape-based virtual screening and structure-based molecular modification.
Sun H; Xu X; Wu X; Zhang X; Liu F; Jia J; Guo X; Huang J; Jiang Z; Feng T; Chu H; Zhou Y; Zhang S; Liu Z; You Q
J Chem Inf Model; 2013 Aug; 53(8):2093-102. PubMed ID: 23937544
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies.
Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A
Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095
[TBL] [Abstract][Full Text] [Related]
13. Optimization of pyrazolo[1,5-a]pyrimidines lead to the identification of a highly selective casein kinase 2 inhibitor.
Krämer A; Kurz CG; Berger BT; Celik IE; Tjaden A; Greco FA; Knapp S; Hanke T
Eur J Med Chem; 2020 Dec; 208():112770. PubMed ID: 32883634
[TBL] [Abstract][Full Text] [Related]
14. ATP site-directed inhibitors of protein kinase CK2: an update.
Sarno S; Papinutto E; Franchin C; Bain J; Elliott M; Meggio F; Kazimierczuk Z; Orzeszko A; Zanotti G; Battistutta R; Pinna LA
Curr Top Med Chem; 2011; 11(11):1340-51. PubMed ID: 21513497
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of protein kinase CK2 by flavonoids and tyrphostins. A structural insight.
Lolli G; Cozza G; Mazzorana M; Tibaldi E; Cesaro L; Donella-Deana A; Meggio F; Venerando A; Franchin C; Sarno S; Battistutta R; Pinna LA
Biochemistry; 2012 Aug; 51(31):6097-107. PubMed ID: 22794353
[TBL] [Abstract][Full Text] [Related]
16. Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy - potential clinical relevance.
D'Amore C; Borgo C; Sarno S; Salvi M
Cell Oncol (Dordr); 2020 Dec; 43(6):1003-1016. PubMed ID: 33052585
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2.
Golub AG; Bdzhola VG; Briukhovetska NV; Balanda AO; Kukharenko OP; Kotey IM; Ostrynska OV; Yarmoluk SM
Eur J Med Chem; 2011 Mar; 46(3):870-6. PubMed ID: 21276643
[TBL] [Abstract][Full Text] [Related]
18. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
19. "Janus" efficacy of CX-5011: CK2 inhibition and methuosis induction by independent mechanisms.
D'Amore C; Moro E; Borgo C; Itami K; Hirota T; Pinna LA; Salvi M
Biochim Biophys Acta Mol Cell Res; 2020 Nov; 1867(11):118807. PubMed ID: 32745724
[TBL] [Abstract][Full Text] [Related]
20. Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach.
Borgo C; Cesaro L; Hirota T; Kuwata K; D'Amore C; Ruppert T; Blatnik R; Salvi M; Pinna LA
Eur J Med Chem; 2021 Mar; 214():113217. PubMed ID: 33548633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]